Then, the active forms of GLP-1 are extremely susceptible to the catalytic activity of the proteolytic enzyme dipeptidyl peptidase-4 (DPP-4), resulting in the abundant inactivated GLP-1 (936) amide constituting 6080% of total GLP-1 in circulation
There was no apparent effect of renal impairment, hepatic impairment or upper GI disease on the PK and tolerability of orally administered semaglutide, suggesting that dose adjustment is not necessary in these special populations [11, 31,32,33]
For instance, preliminary findings from the phase 2 trial of retatrutide, a triple hormone receptor agonist, reported a 100% response rate of more than 5% weight loss for the dosages of 8 or 12 mg weekly over 48 weeks ( Figure 2 To date, little is known about specific predictive factors for treatment response, especially for pharmacotherapy ( Research has indicated that the presence of type 2 diabetes significantly impacts weight loss response ( post-hoc analysis of pooled data from the SCALE Obesity and Prediabetes and SCALE Diabetes trial demonstrated notable differences in the proportion of early responders and early non-responders to liraglutide
The SURPASS-3 MRI substudy demonstrated significant reductions in liver fat content at 52 weeks
.avif)
